Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,829 Lymphoma
clinical trials

AIDS-Related Primary Effusion Lymphoma Clinical Trial
Clinical Factors and Gene Expression Analysis for Prognosis in Tissue Samples From Patients With AIDS-Related Primary Effusion Lymphoma
Status: Enrolling, Phase
Updated: 4/19/2018
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Oncology Clinical Trial
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
Status: Enrolling, Phase I, II
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Hodgkin Lymphoma Clinical Trial
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Hodgkin Lymphoma Clinical Trial
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Oncology Clinical Trial
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Oncology Clinical Trial
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Status: Enrolling, Phase I, II
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology, Otolaryngology Clinical Trial
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Status: Enrolling, Phase III
Updated: 12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology, Otolaryngology Clinical Trial
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Status: Enrolling, Phase III
Updated: 12/31/1969
Massachusetts General Hospital - CURTIS
mi
from
Boston, MA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology, Otolaryngology Clinical Trial
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Status: Enrolling, Phase III
Updated: 12/31/1969
Tulane University Health Sciences Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Oncology Clinical Trial
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Oncology Clinical Trial
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington DC,
Click here to add this to my saved trials
Waldenstrom Macroglobulinemia Clinical Trial
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
Status: Enrolling, Phase II
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Waldenstrom Macroglobulinemia Clinical Trial
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
Status: Enrolling, Phase II
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Oncology Clinical Trial
Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Carolina's HealthCare System's Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Lymphoma Clinical Trial
Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas
Status: Enrolling, Phase I
Updated: 12/31/1969
University Hospitals of Cleveland Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Phase Ib of L-NMMA and Pembrolizumab
Status: Enrolling, Phase I
Updated: 12/31/1969
Houston Methodist Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Mantle-Cell Lymphoma Clinical Trial
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)
Status: Enrolling, Phase III
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Status: Enrolling, Phase II
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Lymphoma Clinical Trial
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Lymphangioleiomyomatosis Clinical Trial
Discovery of Sirolimus Sensitive Biomarkers in Blood
Status: Enrolling, Phase
Updated: 12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Diffuse Large B-Cell Lymphoma Clinical Trial
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
Medical University of South Carolina Hospital
mi
from
Charleston, SC
Click here to add this to my saved trials
Diffuse Large B-Cell Lymphoma Clinical Trial
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Click here to add this to my saved trials
Diffuse Large B-Cell Lymphoma Clinical Trial
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
Southern Cancer Center, PC
mi
from
Daphne, AL
Click here to add this to my saved trials
Diffuse Large B-Cell Lymphoma Clinical Trial
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
Florida Cancer Specialists and Research Institute
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Diffuse Large B-Cell Lymphoma Clinical Trial
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Utah (Huntsman Cancer Hospital)
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Oncology Clinical Trial
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Oncology Clinical Trial
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Oncology Clinical Trial
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Status: Enrolling, Phase II, III
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Oncology Clinical Trial
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology, Rheumatology Clinical Trial
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Children's Hospital at Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology, Rheumatology Clinical Trial
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Childrens National Medical Center
mi
from
Washington DC,
Click here to add this to my saved trials
Oncology Clinical Trial
Sym021 Monotherapy and in Combination With Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Status: Enrolling, Phase I
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Oncology Clinical Trial
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Oncology Clinical Trial
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Oncology Clinical Trial
Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Gastroenterology, Oncology Clinical Trial
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Gastroenterology, Oncology Clinical Trial
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Gastroenterology, Oncology Clinical Trial
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)
Status: Enrolling, Phase I
Updated: 3/19/2018
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)
Status: Enrolling, Phase I
Updated: 3/19/2018
HonorHealth Research Institute
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
Smilow Cancer Hospital of Yale New Haven
mi
from
New Haven, CT
Click here to add this to my saved trials
Lymphoma Clinical Trial
A Study of Parsaclisib in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)
Status: Enrolling, Phase II
Updated: 12/31/1969
USOR - Rocky Mountain Cancer Centers
mi
from
Denver, CO
Click here to add this to my saved trials
Lymphoma Clinical Trial
A Study of Parsaclisib in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)
Status: Enrolling, Phase II
Updated: 12/31/1969
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Status: Enrolling, Phase I, II
Updated: 12/31/1969
UPMC - Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma Clinical Trial
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Comprehensive Cancer Centers
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Lymphoma Clinical Trial
A Study of Parsaclisib in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Status: Enrolling, Phase II
Updated: 12/31/1969
Gettysburg Cancer Center
mi
from
Gettysburg, PA
Click here to add this to my saved trials
Lymphoma Clinical Trial
A Study of Parsaclisib in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Status: Enrolling, Phase II
Updated: 12/31/1969
Arizona Oncology Associates - Biltmore Cancer Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Oncology Clinical Trial
A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL
Status: Enrolling, Phase III
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Oncology Clinical Trial
A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL
Status: Enrolling, Phase III
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Oncology Clinical Trial
A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL
Status: Enrolling, Phase III
Updated: 12/31/1969
Siteman Cancer Center-South County
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
Wexner Medical Center at the Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
University of Utah, Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma
Status: Enrolling
Updated: 12/31/1969
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Status: Enrolling, Phase II
Updated: 12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Sinai Hospital of Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Valley Children's Hospital
mi
from
Madera, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Randall Children's Hospital at Legacy Emanuel
mi
from
Portland, OR
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Dell Children's Medical Center of Central Texas
mi
from
Austin, TX
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Vermont College of Medicine
mi
from
Burlington, VT
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Blank Children's Hospital
mi
from
Des Moines, IA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Mission Hospital-Memorial Campus
mi
from
Asheville, NC
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Dayton Children's Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Miami Miller School of Medicine-Sylvester Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Morristown Medical Center
mi
from
Morristown, NJ
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Sanford USD Medical Center - Sioux Falls
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Providence Sacred Heart Medical Center & Children's Hospital
mi
from
Spokane, WA
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Childrens National Medical Center
mi
from
Washington DC,
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Dell Children's Medical Center of Central Texas
mi
from
Austin, TX
Click here to add this to my saved trials
1 … 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 … 98